Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.51 |
| ▸ | MMP3 | P08254 | 7/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137315 | 0.87 | MMP2 (0.46) | MMP2MMP3EPHX1MMP1 | |
| SCHEMBL5408525 | 0.82 | EPHX1 (0.43) | MMP2EPHX1 | |
| Cyclohexylamine SCHEMBL5408733 | 0.80 | MMP2 (0.46) | MMP2MMP3MMP1 | |
| Cyclohexylamine SCHEMBL5408739 | 0.80 | MMP2 (0.46) | MMP2MMP3MMP1 | |
| SCHEMBL7423179 | 0.78 | MEN1 (0.46) | MMP2MMP3MMP1 | |
| SCHEMBL5400150 | 0.77 | GRIK1 (0.54) | MMP2MMP3MMP1 | |
| SCHEMBL5400156 | 0.77 | GRIK1 (0.54) | MMP2MMP3MMP1 | |
| SCHEMBL6834453 | 0.76 | GRIK1 (0.52) | MMP2MMP3MMP1 | |
| SCHEMBL6834457 | 0.76 | GRIK1 (0.52) | MMP2MMP3MMP1 | |
| SCHEMBL9574086 | 0.75 | MMP2 (0.60) | MMP2MMP3EPHX2EPHX1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1343771-B1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| EP-1373231-B1 | 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| EP-1199301-B1 | Olefination process to itaconate and succinate derivatives | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6831088-B2 | Wound healing agents; antiscarring agents | PFIZER INC. | 2004-12-14 | — | — | US | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | DATTA USA (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | PFIZER, INC | 2002-10-17 | — | — | US | disclosed |
| WO-2002079200-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6452041-B1 | REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| WO-2002050046-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| EP-1199301-A1 | Olefination process to itaconate and succinate derivatives | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | MMP2 16/4885MMP3 8/4885EPHX2 906/4885 |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, HADHA, OGDH | MMP2 2827/4885MMP3 3007/4885EPHX2 2478/4885 |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | ALPI, TIMP3, MMP1 | MMP2 22/4885MMP3 9/4885EPHX2 224/4885 |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | ALPI, TIMP3, MMP1 | MMP2 22/4885MMP3 9/4885EPHX2 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.